Impact of sarcopenia on short- and long-term outcomes after multimodal therapy for esophageal cancer.

Journal of Clinical Oncology 2026

View at publisher
Authors: Lee Ann Santore, Mohamad K. Abou Chaar, Grace Patrice Anyetei-Anum, Belisario A Ortiz, Robert P. Hartman, William Scott Harmsen, Christopher Leigh Hallemeier, Krishan R. Jethwa, Harry H. Yoon, Zhaoui Jin, Mojun Zhu, Carlos A. Puig
+5 more Janani S. Reisenauer, Stephen D. Cassivi, Robert K. Shen, Dennis A. Wigle, Luís Felipe Tapias
DOI: 10.1200/jco.2026.44.2_suppl.334
Cited by: 0

Abstract

334 Background: Sarcopenia, or decreased skeletal muscle mass, has been associated with worse surgical and oncologic outcomes across multiple malignancies. This study investigates the impact of sarcopenia on outcomes after multimodal therapy for esophageal cancer. Methods: Retrospective observational cohort study including adult patients who underwent neoadjuvant therapy followed by esophagectomy for primary esophageal cancer from January 2000 - December 2021. A fully automated abdominal segmentation using deep convolutional neural network was utilized to calculate skeletal muscle index (SMI) from preoperative CT scans performed at our institution. Males with SMI

Fields of Study & Subjects

Nutrition and Health in Aging Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes

Publication details

Journal / source
Journal of Clinical Oncology
Volume
44
Issue
2_suppl
Pages
334–334
Publication date
10 January 2026
Language
EN